ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0670

Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Abstract Number: 0579

Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Abstract Number: 1938

Risk for Vision Loss and Relapse in Patients with Giant Cell Arteritis
Abstract Number: L02

Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
Abstract Number: 0120

Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Abstract Number: 0540

Risk of Hydroxychloroquine Retinopathy in the Community
Abstract Number: 1001

Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Abstract Number: 1005

Risk of Non-vertebral Fractures Among Rheumatoid Arthritis Patients Treated with Biologic or Targeted-Synthetic DMARDs: A Multi-Database Comparative Safety Study
Abstract Number: 1417

Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study
Abstract Number: 0580

Risk of Severe Acute Localized Reactions for Different Intra-Articular Hyaluronic Acid Knee Injections in a Real World Setting
Abstract Number: 2000

Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Abstract Number: 0650

Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout
Abstract Number: 1149

Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)
Abstract Number: 1051

Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers
Abstract Number: 0527

Rituximab for Refractory Manifestations of the Antiphospholipid Syndrome: A Multicenter Israeli Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].